nicardipine has been researched along with Raynaud Disease in 17 studies
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.
nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.
2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.
Raynaud Disease: An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifteen patients with Raynaud's phenomenon [systemic lupus erythematosus (6), progressive systemic sclerosis (8) and rheumatoid arthritis (1)] and 12 patients with Raynaud's disease participated in a parallel, 4-week/arm, double blind, crossover study of nicardipine, an experimental calcium channel blocker." | 5.06 | Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker. ( Dorsey, JK; Furst, DE; Kohler, J; Mellinger, S; Rupp, PA, 1987) |
| "A total of 69 patients with primary Raynaud phenomenon were included in a multicenter, randomized, double-blind, crossover, placebo-controlled trial to assess the efficacy of nicardipine, a new calcium channel blocker." | 2.67 | Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon. French Cooperative Multicenter Group for Raynaud Phenomenon, Paris, France. ( , 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (41.18) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ennis, H | 2 |
| Anderson, ME | 2 |
| Wilkinson, J | 2 |
| Herrick, AL | 2 |
| Hughes, M | 1 |
| Pope, J | 4 |
| Sturgill, MG | 1 |
| Seibold, JR | 1 |
| Ferri, C | 1 |
| Cecchetti, R | 1 |
| Cini, G | 1 |
| Gambini, I | 1 |
| La Civita, L | 1 |
| Bernini, L | 1 |
| Bombardieri, S | 1 |
| Pasero, G | 1 |
| Wollersheim, H | 2 |
| Thien, T | 2 |
| van Heereveld, H | 1 |
| Gough, K | 1 |
| Wigley, FM | 1 |
| Wise, RA | 1 |
| Malamet, R | 1 |
| Scott, TE | 1 |
| Kahan, A | 3 |
| Amor, B | 3 |
| Menkès, CJ | 3 |
| Rupp, PA | 1 |
| Mellinger, S | 1 |
| Kohler, J | 1 |
| Dorsey, JK | 1 |
| Furst, DE | 1 |
| Weber, S | 1 |
| Guérin, F | 1 |
| Degeorges, M | 1 |
| Nakashima, Y | 1 |
| Fujihira, T | 1 |
| Fukuchi, Y | 1 |
| Ishii, N | 1 |
| Imaizumi, T | 1 |
| Miyahara, K | 1 |
| Takasugi, M | 1 |
| Kuroiwa, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Potential Benefit for Non Invasive Vagus Nerve Stimulation (nVNS) Using GammaCore in the Treatment of Raynaud's Phenomena.[NCT03869008] | 7 participants (Actual) | Interventional | 2019-04-30 | Terminated (stopped due to Funding no longer available) | |||
| A Double-blinded, Placebo-controlled, Crossover Study to Assess Efficacy of Oral Treprostinil Titrated to Highest Tolerable Dose in 20 Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon Resistant to Vasodilatory Therapy[NCT02583789] | Early Phase 1 | 12 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| A Randomized, Placebo-controlled Trial of St.John's Wort(a Natural Health Product) in the Treatment on Raynaud's Phenomenon[NCT00351117] | Phase 3 | 20 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for nicardipine and Raynaud Disease
| Article | Year |
|---|---|
Calcium channel blockers for primary Raynaud's phenomenon.
Topics: Calcium Channel Blockers; Humans; Nicardipine; Nifedipine; Randomized Controlled Trials as Topic; Ra | 2014 |
Calcium channel blockers for primary Raynaud's phenomenon.
Topics: Calcium Channel Blockers; Humans; Nicardipine; Nifedipine; Randomized Controlled Trials as Topic; Ra | 2016 |
Raynaud's phenomenon (primary).
Topics: Amlodipine; Diltiazem; Humans; Nafronyl; Nicardipine; Nifedipine; Raynaud Disease; Vasodilator Agent | 2003 |
Raynaud's (primary).
Topics: Humans; Nicardipine; Nifedipine; Raynaud Disease; Vasodilator Agents | 2003 |
Raynaud's phenomenon (primary).
Topics: Humans; Nicardipine; Nifedipine; Raynaud Disease; Vasodilator Agents | 2004 |
Raynaud's phenomenon (primary).
Topics: Humans; Nicardipine; Nifedipine; Raynaud Disease; Vasodilator Agents | 2005 |
8 trials available for nicardipine and Raynaud Disease
| Article | Year |
|---|---|
Slow-releasing nicardipine in the treatment of Raynaud's phenomena without underlying diseases.
Topics: Adult; Aged; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Middle Aged; Ni | 1992 |
Double-blind placebo-controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon.
Topics: Administration, Oral; Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicardipine; Ra | 1991 |
Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon. French Cooperative Multicenter Group for Raynaud Phenomenon, Paris, France.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicardipine; Prospective Studies; Ray | 1991 |
Intravenous nicardipine in Raynaud's phenomenon: a controlled trial.
Topics: Adult; Clinical Trials as Topic; Cold Temperature; Double-Blind Method; Female; Hemodynamics; Humans | 1988 |
Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm.
Topics: Adolescent; Adult; Aged; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; Double-Bli | 1987 |
[Nicardipine in the treatment of Raynaud's phenomenon].
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicardipine | 1987 |
Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Hemod | 1987 |
Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle | 1987 |
3 other studies available for nicardipine and Raynaud Disease
| Article | Year |
|---|---|
Rational use of calcium-channel antagonists in Raynaud's phenomenon.
Topics: Amlodipine; Calcium Channel Blockers; Diltiazem; Felodipine; Humans; Isradipine; Nicardipine; Nifedi | 1998 |
Nicardipine in the treatment of Raynaud's phenomenon.
Topics: Humans; Nicardipine; Raynaud Disease | 1987 |
Autopsy findings of the coronary arteries of variant angina with Raynaud's phenomenon of the tongue.
Topics: Adult; Alprostadil; Angina Pectoris, Variant; Cardiac Catheterization; Coronary Vessels; Drug Therap | 1986 |